Navigation Links
Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures
Date:7/23/2014

t program has involved over 3,000 people and offers over eight years of clinical experience with some patients.1 We look forward to discussing the data with the regulatory authorities and the scientific community."

Based on the results of the brivaracetam Phase 3 program, UCB plans to submit a New Drug Application to the US Food & Drug Administration (FDA) and a Marketing Authorization Application to the European Medicines Agency (EMA) in early 2015.

This Phase 3 study was a randomized, double-blind, placebo-controlled, multicentre, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam (100 and 200 mg/day) compared to placebo, over a 12-week treatment period, in 768 randomized focal epilepsy patients (aged 16 to 80 years) with partial-onset seizures, not fully controlled despite treatment with one or two concomitant AEDs.2,7 The primary endpoint for the European regulatory authorities is the 50% responder rate for partial-onset seizure frequency compared with placebo, over the treatment period standardized to a 28-day duration. The primary endpoint for the FDA is the percent reduction over placebo for partial-onset seizure frequency, over the treatment period standardized to a 28-day duration.2 Detailed data from this study will be submitted for presentation at upcoming epilepsy congresses and for publications in peer-reviewed journals.

About brivaracetam and the Phase 3 clinical development program Discovered and developed by UCB, brivaracetam is a highly selective synaptic vesicle protein 2A ligand.8,9

The phase 3 clinical development plan for brivaracetam consisted of the following studies:N01252: an evaluation of the efficacy and safety/tolerability of adjunctive brivaracetam 20, 50, and 100 mg/day compared with placebo over 12 weeks, in 399 randomized patients (greater than or equal to 16 to 70 yea
'/>"/>

SOURCE UCB
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Majority of Biotech/Pharma Employees Poised to Job Hunt
2. ZenCash Plucks Top Executives from Major DFW Brands
3. Accelerated Cure Project for Multiple Sclerosis Approved for Major Funding Award from Patient-Centered Outcomes Research Institute to Create MS Patient-Powered Research Network
4. Clinovo Rolls Out Major Enhancements for Open Source EDC ClinCapture at Outsourcing in Clinical Trials West Coast Conference
5. Verified Clinical Trials Stops Dual Enrollment in Clinical Trials in Major CNS Clinical Trials to Reduce Potential Adverse Events and Improve Data Quality
6. Major CRO Gives Top Ratings To Verified Clinical Trials To Stop Dual Enrollment In Clinical Trials On Late Phase Trial
7. Kibow Biotech Achieves Major Victory with Indias IPAB Decision to Uphold 2009 Product Patent
8. Sales Momentum Introduces 5 Payoffs to Asking Questions in Sales Calls in a White Paper - Mastering Major Account Selling
9. Dyadic International To Present At Two Major Conferences In December 2013
10. Sales Momentum Shares Three Common Pitfalls to Avoid When Developing Major Account Sales Strategies
11. The Blazing Diamond and the Quantum Jewel: Two Major Discoveries in Quick Succession
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Hungary , September 30, 2014 ... and intuitive browsing of chemistry in documents ... chemistry software solutions and consulting services for life ... chemical information and generate Markush structures from documents. ... an organizations intellectual property, however generating and understanding ...
(Date:9/30/2014)... Calif. , Sept. 30, 2014 FemCap ... women,s health announces its receipt of a patent No: ... menstrual cup has also received FDA clearance in the ... and the CE in Europe. This patent is related to ... with this issuance, the company is releasing FemmyCycle Teen, ...
(Date:9/30/2014)... Boston, MA (PRWEB) September 30, 2014 ... communications (UC) and collaboration company is dedicated to ... data connectivity needs. Julie Power, a ... team to ensure collaboration solutions stays connected and ... response to the increased movement of businesses to ...
(Date:9/30/2014)... September 30, 2014 Back in the 1970’s, ... square feet. per employee, which included space for circulation and ... says Jeff Howell, partner at Nidea Corporate Real Estate ... Toronto. “By the year 2000, however, 250 square feet ... that number come down to 175 to 225 square feet, ...
Breaking Biology Technology:ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2The FemmyCycle 2SoundConnect Expands Carrier Services Division 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3
... Olive Branch Fund: A Thisbe and Noah Scott Legacy, ... today announced its first funding award to Kevin Eggan, ... at Harvard University.  The award will support Dr. Eggan,s ... that affect it.  Dr. Eggan is a leading researcher ...
... PRINCETON, N.J., June 29, 2011 PharmaNet Development Group, Inc. ... its cash tender offer and consent solicitation (the "Offer") for ... Notes due 2017 (the "Notes"), it has elected to extend ... York City time, on July 6, 2011, unless extended or ...
... Associates® - San Francisco, a specialized executive search firm ... arena, welcomes Eduard Alberts, Ph.D. as Vice President and ... of experience and success in the life sciences industry, ... companies and a wide array of cultures. His prior ...
Cached Biology Technology:The Olive Branch Fund Announces Funding Award to Harvard Researcher 2PharmaNet Extends Expiration Time in its Tender Offer and Consent Solicitation 2PharmaNet Extends Expiration Time in its Tender Offer and Consent Solicitation 3Eduard Alberts, Ph.D. Joins Sanford Rose Associates - San Francisco 2
(Date:9/30/2014)... on Earth, but when the climate changes and temperatures ... The amount of time needed to adjust to new ... in the future, reveals a new study from researchers ... journal Proceedings of the Royal Society B . ... of greenhouse gases in the atmosphere. The greenhouse effect ...
(Date:9/30/2014)... you want your doctor to know what goes wrong with ... good idea to know what "normal" actually is. That,s where ... of the FASEB Journal comes in. ... transcriptomea key set of molecules that can help scientists "see" ... time. What,s more, they found never-before-detected gene activity and that ...
(Date:9/30/2014)... 2014) People who suffer from asthma may think ... their asthma besides properly taking medications and avoiding allergic ... the Annals of Allergy, Asthma and Immunology , ... Asthma and Immunology (ACAAI), asthma sufferers can learn lessons ... woman described in the Annals article improved her asthma ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Scientists identify which genes are active in muscles of men and women 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... penguins in Antarctica than was previously thought, according to ... of researchers using high-resolution satellite mapping technology. This first-ever ... important benchmark for monitoring the impact of environmental change ... from the University of Minnesota Polar Geospatial Center co-authored ...
... press release is available in German . , ... beings in their own right. This changed about one billion years ... cells. Since then, they have lost much of their autonomy. As ... into the cell nucleus; today, chloroplasts would no longer be able ...
... Calif.All animals seem to have ways of exchanging informationmonkeys ... and fireflies light up their bellies to attract mates. ... among the most abundant animals on the planet, little ... led by California Institute of Technology (Caltech) biologists has ...
Cached Biology News:Scientists complete first-ever emperor penguin count from space 2Direct transfer of plant genes from chloroplasts into the cell nucleus 2Decoding worm lingo 2Decoding worm lingo 3
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
POU domain, class 2, transcription factor 2,...
Biology Products: